Alexza Pharmaceuticals to Present at Antiepileptic Drug and Device Trials (AED) XII Conference Highlighting Advances in the

  Alexza Pharmaceuticals to Present at Antiepileptic Drug and Device Trials
   (AED) XII Conference Highlighting Advances in the Treatment of Epilepsy

PR Newswire

MOUNTAIN VIEW, Calif., May 6, 2013

MOUNTAIN VIEW, Calif., May 6, 2013 /PRNewswire/ -- Alexza Pharmaceuticals,
Inc. (Nasdaq: ALXA) announced today that the Company has been selected to
present its AZ-002 (Staccato^® alprazolam) program at the Pipeline Session of
the Antiepileptic Drug and Device Trials (AED) XII Conference, the premier
conference devoted to convening the full spectrum of research, industry and
regulatory expertise in the epilepsy field with the objective of accelerating
the most promising epilepsy therapies in development. The three-day AED XII
conference will feature clinical and scientific thought leaders addressing
antiepileptic drug and medical technology development from preclinical-
through late-stage clinical programs. The conference will take place on May
15-17, 2013 at the Turnberry Isle Miami Hotel, Aventura, Florida. James V.
Cassella, PhD, Alexza Executive Vice President, Research and Development and
Chief Scientific Officer will be speaking at 1:45 p.m. Eastern Time on Friday,
May 17, 2013.

According to the Epilepsy Foundation, with nearly three million affected in
the U.S. alone, epilepsy is as common as breast cancer and almost as prevalent
as Alzheimer's disease.

"We are excited that Alexza's AZ-002 product candidate will be highlighted in
the Pipeline Session at the AED XII Conference before such a high caliber
group of scientific, clinical and industry representatives," said James V.
Cassella, PhD. "Staccato alprazolam is being developed for the treatment of
acute repetitive seizures (ARS). ARS occurs in a small subset of patients
with epilepsy who regularly experience breakthrough seizures in flurries or
clusters, despite treatment with a regimen of anti-epileptic drugs."

"Now in its twelfth year, the Antiepileptic Drug and Device Trials XII
Conference spans the range of topics in epilepsy research and development as
one of the leading scientific forums in the field. Offering the most current
thinking on the treatment, diagnosis, global regulatory environment and
therapies in development, AED XII provides a forum for the acceleration of new
treatments and treatment practices that we hope will ultimately benefit people
with epilepsy and seizure disorders," said Jacqueline French, MD, Director of
the Epilepsy Study Consortium, Director of Clinical Trials at NYU's
Comprehensive Epilepsy Center and current President of the American Epilepsy

AED XII is sponsored by the Epilepsy Study Consortium in collaboration with
the University of Pennsylvania Epilepsy Center and the Epilepsy Therapy
Project, an initiative of the Epilepsy Foundation. For additional information
on the AED XII program and speakers or to register, please visit

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is focused on the research, development and
commercialization of novel, proprietary products for the acute treatment of
central nervous system conditions, including agitation, acute repetitive
seizures and insomnia. Alexza's products are based on the Staccato^® system,
a hand-held inhaler that is designed to deliver a drug aerosol to the deep
lung, providing rapid systemic delivery and therapeutic onset with ease and
convenience for patients.

ADASUVE^® (Staccato loxapine) is Alexza's first product, which was approved by
the U.S. Food and Drug Administration in December 2012 and by the European
Medicines Agency in February 2013. Grupo Ferrer Internacional, S.A. is
Alexza's commercial partner for ADASUVE in Europe, Latin America, Russia and
the Commonwealth of Independent States countries.

For more information about Alexza, the Staccato system technology or the
Company's development programs, please visit For more
information about ADASUVE, please visit

ADASUVE^® and Staccato^® are registered trademarks of Alexza Pharmaceuticals,

Safe Harbor Statement

This news release and the upcoming presentation will contain forward-looking
statements that involve significant risks and uncertainties. Any statement
describing the Company's expectations or beliefs is a forward-looking
statement, as defined in the Private Securities Litigation Reform Act of 1995,
and should be considered an at-risk statement. Such statements are subject to
certain risks and uncertainties, particularly those inherent in the process of
developing and commercializing drugs, including the adequacy of the Company's
capital to support the Company's operations, and the Company's ability to
raise additional funds and the potential terms of such potential financings,
the ability for Alexza and Ferrer to effectively and profitably commercialize
ADASUVE and the timing of the projected commercialization of ADASUVE. The
Company's forward-looking statements also involve assumptions that, if they
prove incorrect, would cause its results to differ materially from those
expressed or implied by such forward-looking statements. These and other risks
concerning Alexza's business are described in additional detail in the
Company's Annual Report on Form 10-K for the year ended December 31, 2012 and
the Company's other Periodic and Current Reports filed with the Securities and
Exchange Commission. Forward-looking statements contained in this announcement
are made as of this date, and the Company undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new information,
future events or otherwise.

SOURCE Alexza Pharmaceuticals, Inc.

Contact: BCC Partners, Karen L. Bergman and Michelle Corral, 650.575.1509 or
415.794.8662, or
Press spacebar to pause and continue. Press esc to stop.